(HealthDay)—For men with a prostate-specific antigen (PSA)-only-based relapse after prostate surgery or radiation therapy, there seems to be little or no survival benefit for immediate initiation of androgen deprivation therapy (ADT). These findings have been released in advance of presentation at the annual meeting of the American Society of Clinical Oncology, held from May 30 to June 3 in Chicago.
Xabier Garcia-Albeniz, M.D., from the Harvard School of Public Health in Boston, and colleagues examined the optimal timing to start ADT in patients with rising PSA as the only sign of relapse. Participants included 2,022 men in the Cancer of the Prostate Strategic Urologic Research Endeavor, staged
The researchers found that for immediate versus deferred ADT, the hazard ratio for all-cause mortality was 1.06 (95 percent confidence interval, 0.59 to 1.89), corresponding to a −5.5 percent survival difference at five years. The hazard ratio for prostate-cancer specific mortality was 1.48 (95 percent confidence interval, 0.69 to 3.16), corresponding to a −5.6 percent survival difference.
"These findings suggest that there may be no need to rush to ADT," Garcia-Albeniz said in a statement.
The study was partially funded by a grant from Abbott.
Explore further: Benefit of aggressive prostate CA Tx weakens as comorbidity rises